scholarly journals Pancreatic β‐cell fate in subjects with COVID‐19

Author(s):  
Jun Shirakawa
Keyword(s):  
Cell Cycle ◽  
2008 ◽  
Vol 7 (10) ◽  
pp. 1343-1347 ◽  
Author(s):  
James D Johnson ◽  
Emilyn U. Alejandro

2012 ◽  
Vol 16 (4) ◽  
pp. 449-461 ◽  
Author(s):  
Jakob Bondo Hansen ◽  
Morten Fog Tonnesen ◽  
Andreas Nygaard Madsen ◽  
Peter H. Hagedorn ◽  
Josefine Friberg ◽  
...  

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Grace Hui Ting Yeo ◽  
Sachit D. Saksena ◽  
David K. Gifford

AbstractExisting computational methods that use single-cell RNA-sequencing (scRNA-seq) for cell fate prediction do not model how cells evolve stochastically and in physical time, nor can they predict how differentiation trajectories are altered by proposed interventions. We introduce PRESCIENT (Potential eneRgy undErlying Single Cell gradIENTs), a generative modeling framework that learns an underlying differentiation landscape from time-series scRNA-seq data. We validate PRESCIENT on an experimental lineage tracing dataset, where we show that PRESCIENT is able to predict the fate biases of progenitor cells in hematopoiesis when accounting for cell proliferation, improving upon the best-performing existing method. We demonstrate how PRESCIENT can simulate trajectories for perturbed cells, recovering the expected effects of known modulators of cell fate in hematopoiesis and pancreatic β cell differentiation. PRESCIENT is able to accommodate complex perturbations of multiple genes, at different time points and from different starting cell populations, and is available at https://github.com/gifford-lab/prescient.


2020 ◽  
Vol 34 (S1) ◽  
pp. 1-1
Author(s):  
Aneta Maria Dobosz ◽  
Justyna Janikiewicz ◽  
Anna Maria Borkowska ◽  
Wojciech Maria Kwiatek ◽  
Agnieszka Dobrzyn

2019 ◽  
Vol 133 (22) ◽  
pp. 2317-2327 ◽  
Author(s):  
Nicolás Gómez-Banoy ◽  
James C. Lo

Abstract The growing prevalence of obesity and its related metabolic diseases, mainly Type 2 diabetes (T2D), has increased the interest in adipose tissue (AT) and its role as a principal metabolic orchestrator. Two decades of research have now shown that ATs act as an endocrine organ, secreting soluble factors termed adipocytokines or adipokines. These adipokines play crucial roles in whole-body metabolism with different mechanisms of action largely dependent on the tissue or cell type they are acting on. The pancreatic β cell, a key regulator of glucose metabolism due to its ability to produce and secrete insulin, has been identified as a target for several adipokines. This review will focus on how adipokines affect pancreatic β cell function and their impact on pancreatic β cell survival in disease contexts such as diabetes. Initially, the “classic” adipokines will be discussed, followed by novel secreted adipocyte-specific factors that show therapeutic promise in regulating the adipose–pancreatic β cell axis.


2011 ◽  
pp. 5-10
Author(s):  
Huu Dang Tran

The incretins are peptide hormones secreted from the gut in response to food. They increase the secretion of insulin. The incretin response is reduced in patients with type 2 diabetes so drugs acting on incretins may improve glycaemic control. Incretins are metabolised by dipeptidyl peptidase, so selectively inhibiting this enzyme increases the concentration of circulating incretins. A similar effect results from giving an incretin analogue that cannot be cleaved by dipeptidyl peptidase. Studies have identified other actions including improvement in pancreatic β cell glucose sensitivity and, in animal studies, promotion of pancreatic β cell proliferation and reduction in β cell apoptosis.


Sign in / Sign up

Export Citation Format

Share Document